Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?
- PDF / 545,120 Bytes
- 9 Pages / 610 x 792 pts Page_size
- 23 Downloads / 189 Views
Open Access
Research
Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm? A Simon Pickard*1, Zhixiao Wang1, Surrey M Walton1 and Todd A Lee2,3 Address: 1Center for Pharmacoeconomic Research, College of Pharmacy, Room 164, 833 S. Wood St (MC886), University of Illinois at Chicago, Chicago, IL, 60612 USA, 2Midwest Center for Health Services and Policy Research, Hines VA Hospital, Hines, Illinois, USA and 3Center for Healthcare Studies and Division of General Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Email: A Simon Pickard* - [email protected]; Zhixiao Wang - [email protected]; Surrey M Walton - [email protected]; Todd A Lee - [email protected] * Corresponding author
Published: 04 March 2005 Health and Quality of Life Outcomes 2005, 3:11
doi:10.1186/1477-7525-3-11
Received: 03 January 2005 Accepted: 04 March 2005
This article is available from: http://www.hqlo.com/content/3/1/11 © 2005 Pickard et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract Background: Cost utility analysis (CUA) using SF-36/SF-12 data has been facilitated by the development of several preference-based algorithms. The purpose of this study was to illustrate how decision-making could be affected by the choice of preference-based algorithms for the SF-36 and SF-12, and provide some guidance on selecting an appropriate algorithm. Methods: Two sets of data were used: (1) a clinical trial of adult asthma patients; and (2) a longitudinal study of post-stroke patients. Incremental costs were assumed to be $2000 per year over standard treatment, and QALY gains realized over a 1-year period. Ten published algorithms were identified, denoted by first author: Brazier (SF-36), Brazier (SF-12), Shmueli, Fryback, Lundberg, Nichol, Franks (3 algorithms), and Lawrence. Incremental cost-utility ratios (ICURs) for each algorithm, stated in dollars per quality-adjusted life year ($/QALY), were ranked and compared between datasets. Results: In the asthma patients, estimated ICURs ranged from Lawrence's SF-12 algorithm at $30,769/QALY (95% CI: 26,316 to 36,697) to Brazier's SF-36 algorithm at $63,492/QALY (95% CI: 48,780 to 83,333). ICURs for the stroke cohort varied slightly more dramatically. The MEPS-based algorithm by Franks et al. provided the lowest ICUR at $27,972/QALY (95% CI: 20,942 to 41,667). The Fryback and Shmueli algorithms provided ICURs that were greater than $50,000/QALY and did not have confidence intervals that overlapped with most of the other algorithms. The ICURbased ranking of algorithms was strongly correlated between the asthma and stroke datasets (r = 0.60). Conclusion: SF-36/SF-12 preference-based algorithms produced a wide range of ICURs that could potentially lead to different reimb
Data Loading...
